 Braxia Scientific Corp announced its CEO, Roger McIntyre, and chief medical officer, Josh Rosenblat, has received C918,000 in funding from the Government of Canadas Canadian Institutes of Health Research for ketamine research. In a statement, Toronto-based Braxia said that the funding will go towards studying the effectiveness of intravenous ketamine in combination with internet-based cognitive behavioural therapy CBT to reduce suicidality in people living with depression. 